A password will be e-mailed to you.

FDA Declares Kratom To Be An Opioid – Kratomaton Biweekly Update: February 16th, 2018

Love is in the air!

Hello and welcome to the Kratomaton Biweekly update for February 16th, 2018!

Even though it’s the season of love, all is not well in the world of kratom! Earlier this month, the United States Food and Drug Administration released a follow-up statement to their initial kratom public health advisory. This latest update is chock-full of assertions that challenge public perceptions of kratom’s properties and usages. Most notably, the FDA has deemed kratom to be an opioid, based on their research. We’ll have more on that – along with some good news (thankfully) – in this edition of the Kratomaton bi-weekly update! Let’s get started.  

KRATOM IN THE NEWS

“Kratom … isn’t just a plant – it’s an opioid.” – FDA

In this latest FDA statement on kratom, the department has deemed kratom to be an opioid based on the “novel scientific analysis” they’ve conducted. Using a 3D computer simulation they refer to as “PHASE,” the FDA has announced that they’re confident in calling kratom an opioid, due to chemical similarities:
… scientists at the FDA first analyzed the chemical structures of the 25 most prevalent compounds in kratom. From this analysis, the agency concluded that all of the compounds share the most structural similarities with controlled opioid analgesics, such as morphine derivatives. 
The post goes on to state:
Based on the scientific information in the literature and further supported by our computational modeling and the reports of its adverse effects in humans, we feel confident in calling compounds found in kratom, opioids.
However, later in the statement, the FDA also makes a further assertion about what kratom is:
… as the scientific data and adverse event reports have clearly revealed, compounds in kratom make it so it isn’t just a plant – it’s an opioid.
While the term “opioid” can be used in reference to a broad range of substances that bind to opioid receptors in the brain, the term is typically associated with synthetic substances. Research has regularly demonstrated that, indeed, kratom does contain compounds that bind to opioid receptors in the brain. However, strictly labelling kratom “an opioid” because it’s an agonist of this particular receptor is dismissive of its distinctive chemical properties. Opioid comparisons were explored in “Update on the Pharmacology and Legal Status of Kratom,” (2016) where, based on existing science, the paper’s author observed the following:
At the molecular level, mitragynines are structurally quite different from traditional opioids such as morphine. Moreover, recent studies indicate that even though the mitragynines can interact with opioid receptors, their molecular actions are different from those of opioids.
It’s unclear if the FDA is committed to labelling kratom as an “opioid” simply due to a lack of additional substance classification terminology, or if the news is meant to publically stigmatize kratom in a tumultuous era of widespread opioid addiction. Regardless, the classification in itself is a bold statement. Within the press release, Gottlieb also expressed the FDA’s disinterest in kratom’s medical usage, citing that the substance does not meet the “[FDA’s] standard for approval:”
The FDA stands ready to evaluate evidence that could demonstrate a medicinal purpose for kratom. However, to date, we have received no such submissions and are not aware of any evidence that would meet the agency’s standard for approval. Kratom should not be used to treat medical conditions, nor should it be used as an alternative to prescription opioids. There is no evidence to indicate that kratom is safe or effective for any medical use.
However, the FDA also restated their commitment to FDA approved drugs, specifying buprenorphine, methadone, and naltrexone as suitable treatments for opioid addiction. At this point, kratom’s legality within the United States seems to be tentative. It’s uncertain what the next few months will hold regarding changes in policy and perception. If you’re a United States citizen interested in defending kratom’s legality, please visit the links below:

American Kratom Association

Botanical Education Alliance

 

DISCOUNTS & SALES

Buy Kratom Bulk USA

Due to kratom’s pending illegality in Kansas, USA, Buy Kratom Bulk USA is offering 20% off with coupon “Kansas20,” from now until the 22nd of February.

Click here to check them out!

Use discount code Kansas20 for 20% off until February 22nd, 2018!

You can read more about the pending legislation in Kansas and take action here!  

VENDOR UPDATES

New Vendors

We’ve added a few new vendors since our last update on January 31st:

Black Flag Botanicals

February 12, 2018

Kratom For Sale

February 5, 2018  

Trusted Vendors

We’d also like to congratulate the following vendors for confirming their Trusted Vendor status here on Kratomaton! Kudos to them for their cooperation and steadfast commitment to the online kratom community at large:

Christopher’s Organic Botanicals

HCK Wellness

Buy Kratom Bulk USA

February 8, 2018  

STRAIN UPDATES

No new strains were added since the last update! If we’re totally slacking and missed one, let us know!  

SITE UPDATES

New blog: The Best Way To Store Kratom

A new blog post is up! Read up on four unique kratom storage solutions and how they can help you preserve and protect your kratom products.
  That’s it for this week’s update.  Thanks for reading! Love, Kratomaton  

Works Cited

Gottlieb, S. (n.d.). February 6th, 2018 Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse [WebContent]. Retrieved February 16, 2018, from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm595622.htm
Prozialeck, W. C. (2016). Update on the Pharmacology and Legal Status of Kratom. The Journal of the American Osteopathic Association, 116(12), 802. https://doi.org/10.7556/jaoa.2016.156